WS Investor
07 Apr 2026, 19:19
Gilead Sciences, Inc. announced it will acquire Tubulis GmbH in a deal valued at up to $5 billion, strengthening its oncology pipeline.
The transaction includes $3.15 billion in upfront cash and up to $1.85 billion in milestone payments. Tubulis brings a next-generation antibody-drug conjugate (ADC) platform and clinical-stage assets, including TUB-040, currently in development for ovarian and lung cancers.
Gilead said the acquisition will enhance its capabilities in targeted cancer therapies by adding advanced ADC technologies designed to improve drug delivery and treatment outcomes.
The deal is expected to close in the second quarter of 2026, subject to regulatory approvals, with Tubulis to operate as a dedicated research unit within Gilead.
Business Wire
The transaction includes $3.15 billion in upfront cash and up to $1.85 billion in milestone payments. Tubulis brings a next-generation antibody-drug conjugate (ADC) platform and clinical-stage assets, including TUB-040, currently in development for ovarian and lung cancers.
Gilead said the acquisition will enhance its capabilities in targeted cancer therapies by adding advanced ADC technologies designed to improve drug delivery and treatment outcomes.
The deal is expected to close in the second quarter of 2026, subject to regulatory approvals, with Tubulis to operate as a dedicated research unit within Gilead.
Business Wire